presentation of 2007 results
play

Presentation of 2007 Results 15th F e b rua ry 2008 CONT E NT - PowerPoint PPT Presentation

Presentation of 2007 Results 15th F e b rua ry 2008 CONT E NT S 1 | PCAS GROUP 2 | 2007 RE SUL T S 3 | PHARMACE UT ICAL SYNT HE SIS 4 | F INE SPE CIAL IT Y CHE MICAL S 5 | RE SE ARCH & DE VE L OPME NT 6 | OUT L


  1. Presentation of 2007 Results 15th F e b rua ry 2008

  2. CONT E NT S 1 | PCAS GROUP 2 | 2007 RE SUL T S 3 | PHARMACE UT ICAL SYNT HE SIS 4 | F INE SPE CIAL IT Y CHE MICAL S 5 | RE SE ARCH & DE VE L OPME NT 6 | OUT L OOK PCAS – F e b rua ry 2008 | 2

  3. 1 | PCAS GROUP

  4. PCAS GROUP A c le ar position c e ntr e d on 2 ac tivitie s Phar mac e utic al F ine Spe c iality Synthe sis Che mic a ls Manufacturer of complex, very high-added value molecules, sold around the world and applying leading-edge technology PCAS – F e b rua ry 2008 | 4

  5. PCAS An inte r national Gr oup Site s loc ation 4 Pha rma c e utic a l Synthe sis site s (a ll F DA inspe c te d) 2 po lyva le nt site s (Bo urg o in a nd Co ute rne : I SO 9001) 2 F ine Spe c ia lity Che mic a ls site s (Sa int Je a n I SO 9001) He a dq ua rte r situa te d in L o ng jume a u (ne a r Pa ris) PCAS – F e b rua ry 2008 | 5

  6. PCAS GROUP An inte r national Gr oup Sale s br e ac kdown 2007Ne t Sa le s : 185.3 M€ Othe rs 2.6% Asia- Pac ific 17.0% Franc e 34.3% North Ame ric a 10.3% Europe 35.8% Phar mac e utic al Synthe sis : 109.4M€ F ine Spe c iality Che mic als: 75.9M€ PCAS – F e b rua ry 2008 | 6

  7. PCAS GROUP An e xc e ptional por tfolio of c lie nts Pharmaceutical Synthesis PCAS – F e b rua ry 2008 | 7

  8. PCAS GROUP An e xc e ptional por tfolio of c lie nts Perfumery-Aroma-Cosmetics Performane Chemicals New Technologies PCAS – F e b rua ry 2008 | 8

  9. PCAS GROUP Histor y PCAS c re a te d b y 2 F re nc h e ntre pre ne urs � 1962 PCAS jo ins Sta uffe r Che mic a ls the n Akzo No b e l � 1982 he Dyna c tion Group a c quire s PCAS fo r 8.3 M€ � 1992 T Ac q uisitio n o f Sa int- Je a n Photoc himie ( Que b e c ) � 1993 Introduc tion o n the « se c o nd ma rc hé » o f the Pa ris sto c k e xc ha ng e va luing PCAS a t 23 M€ � 1995 SBS c re a te d, spe c ia lising in the pro duc tio n o f a c role in de riva tive s � 1996 1998 Ac q uisitio n o f Se lo c F ra nc e ( L ima y ) spe c ia lising in Pha rma c e utic a l Synthe sis (no w me rg e d � with PCAS) 1999 Ac q uisitio n o f PCF (Mine ra l Che mic a ls) a nd o f Ve rno la b � 2001 Ac q uisitio n o f E inland a nd o f Cre a pha rm � xpansia, of PCAS F Sa le o f Ve rno la b to the SGS Gro up – 85% purc ha se o f VL G Che m (Sa no fi-Ave ntis ma inta ining � 2004 15% o f the c a pita l) – PCAS Ame r ic a Inc c re a te d 2005 Sa le o f Cre a pha rm � PCAS Biosolution c re a te d – inte re st ta ke n in Pro té us (6%)– Sa le o f a ma jo rity sta ke in PCF to � 2006 ma na g e me nt 2007 I nte re st in Proté us c a pita l inc re a se d to 32% - I nte re st in PCF c a pita l re duc e d to 19.9% � PCAS – F e b rua ry 2008 | 9

  10. PCAS GROUP Shar e holding Capital distribution Source : TPI 31st December 2007 Dyna c ti o n Ma na g e me nt Pub l ic T re a sury sto c ks 1,65% 29,61% 0,95% 67,79% Other information I sin c o de F R 0000053514 – PCA As o f 31st Ja nua ry 2007 : Numb e r o f sha re s 13 003 882 Ma rke t c o mpa rtme nt E uro ne xt C Pric e 4,10 € Ma rke t va lue 53,3 M€ PCAS – F e b rua ry 2008 | 10

  11. PCAS GROUP L e gal str uc tur e St Je an Photoc himie St-Je an/Ric he lie u Site Soc ié té Bé ar naise (Canada) VL G c he m de Synthè se Site de Ville ne uve - la-Gare nne 100 % Mo ure nx Site Site (Hauts de Se ine ) (Pyré né e s Atlantique s) 85 % 100 % (Sano fi Ave ntis 15 %) PCAS SA Phar mac ie Ce ntr ale de F ranc e L o ng jume au (E sso nne ) E xpansia L a Vo ulte / Rhô ne Site Co ute rne (Orne ) Aramo n Site (Ardè c he ) Bo urg o in (I sè re ) (Gard) 19,9 % L imay (Yve line s) 100 % (Manag e me nt 80,1 %) Site s PCAS Biosolution PCAS Ame ric a Inc ( L o ng jume au and de Nîme s site s ) (Sale s Org anisatio n - 50 % USA) (Pro té us 50 %) 100 % 50 % Pr oté us PCAS F inland Oy (Nîme s) T urku Site (F inlande ) 32 % 100 % PCAS – F e b rua ry 2008 | 11

  12. PCAS GROUP Or ganisation c har t Chairman Huma n Re so urc e s Ge ne r al Dir e c tor Pharma c e utic al F ine Spe c iality Synthe sis Che mic als Suppor t F unc tions Sa le s & Ma rke ting Sa le s & Ma rke ting Administr ation Ville ne uve E ur ope Coute rne Pe r for manc e IT & F inanc e L a Gare nne Asie c he mic als Re se ar c h & L ima y Bour g oin- Ja llie u De ve lopme nt Sa le s & Ma rke ting Sa le s & Ma rke ting USA F r agr anc e - Non e xc lusive F lavour s- Cosme tic s Ar amon Moure nx Purc hasing Sa le s & Ma rke ting Quality Assur anc e Sa le s & Ma rke ting T urku USA SJPC Ne w T e c hnologie s Re gulatory Affair s (F INL AND) E xc lusive (CANADA) PCAS – F e b rua ry 2008 | 12 Co mité E xé c utif

  13. 2 | 2007 RE SUL T S

  14. 2007 RE SUL T S 2007 Signific ant E ve nts Project launch to Major cooperation implement new ERP agreement signed in Interest in Protéus capital software (JD Edwards). the field of organic increased to 32%. 1.7 M€ investment. photovoltaïcs. Possibility to increase to around 50% (BSA). January 2007 June 2007 October 2007 December 2007 1 st January 2008 Interest in PCF capital reduced to New debt structure : 19.9% • 36 M€ loan over 6 years • 20 M€ OBSAR Start up of new ERP software (JD Edwards) PCAS – F e b rua ry 2008 | 14

  15. 2007 RE SUL T S All financ ial indic ator s ar e at gr e e n Ne t sale s : Ne t de bt re duc e d fro m 79.0 M€ . + 3.9 % a t 185.3 M€ to 70.1 M€ . + 5.3 % a t a c o nsta nt e xc ha ng e ra te Re sults stro ng ly inc re a sing a nd c o nfo rming to o b je c tive s : Obje c tive s : . E BI T : +51.9 % to 12.0 M€ ROC : 8 % of ne t sale s . E BI T DA : + 22.4 % to 26.8 M€ E BIT DA : 15 % of ne t sa le s PCAS – F e b rua ry 2008 | 15

  16. 2007 RE SUL T S 2007 Ne t Sale s + 3.9 % (+ 5.3 % at a constant exchange rate) 185,3 178,3 I n millio ns o f e uro s 2007 2006 185.3 178.3 Ne t sa le s 100 % 100 % 109.4 109.9 Phar mac e utic al Synthe sis 59.1% 61.7% 75.9 68.4 F ine Spe c iality Che mic als 40.9% 38.3% 11% g ro wth in ne t sa le s fo r the F ine Spe c ia lity Che mic a ls po le � Bo o ste d b y the Pe rfume ry-Aro ma -Co sme tic s a nd Pe rfo ma nc e Che mic a ls a c tivitie s � Pha rma c e utic a l Synthe sis po le ’ s ne t sa le s a re sta b le � PCAS – F e b rua ry 2008 | 16

  17. 2007 RE SUL T S 2007 E BIT and E BIT DA Greatly increasing profitability – first effects of actions carried out : . margin improvement . cost reduction + 22.4 % + 51.9 % 26,8 21,9 12,0 7,9 EBIT EBITDA PCAS – F e b rua ry 2008 | 17

  18. NE W DE BT ST RUCT URE Re payme nt of 58.8 M€ syndic ate loan � Re payme nt of the 2007 due amount re garding our forme r syndic ate d loan for 4.8 M€ � A ne w syndic a te loa n for 36 M€ ove r 6 ye a rs � An OBSAR issue (Bonds with e quity wa rra nts a tta c he d) for a ne t a mount of 19.3 M€: � - 11.3 % No mina l unit va lue : 600 e uro s � Numb e r o f OBSAR : 33 333 79,0 � Numb e r o f BSAR : 3 333 300 70,1 � E xpiry : 31st De c e mb e r 2012 � I nte re st’ s ra te : 5,25% � Re pa yme nt pric e : 606 e uro s � BSAR e xe rc ise pric e : 6.90 e uro s � BSAR e xe rc ise pe rio d: a t a ny time up to the 31st De c e mb e r 2012 Conforming to c urre ntly e nforc e d IF RS rule s, this hybride de bt inte g ra te s a de bt pa rt a nd a n e quity pa rt whic h rise to 17.6 million e uros a nd 1.3 million e uros (ta king a c c ount de ffe re d ta xe s) a s of 31st De c e mbe r 2007, re spe c tive ly. PCAS – F e b rua ry 2008 | 18

  19. 2007 RE SUL T S Ke y F igur e s I n millio ns o f e uro s 2007 2006 2005 Ne t sale s 185.3 178.3 170.6 E BI T DA 26.8 21.9 18.4 c e ntage of ne t sale s as a pe r 14.5 % 12.3% 10.8% EBITDA : + 22.4 % De pre c ia tio n a nd pro visio ns (14.8) (14.0) (14.0) ating inc ome (1) Cur r e nt ope r 12.0 7.9 3.9 as a pe r c e ntage of ne t sale s 6.2 % 4.4% 2.31% ROC : + 51.9 % Othe r o pe ra ting inc o me and e xpe nse s (2) (3.0) (0.8) (0.5) Ne t inte re st e xpe nse o n de b t (4.7) (4.0) (3.9) Ne t pr ofit 2.7 1.2 (2.5) Ne t pr ofit – exc luding impac t of fr e e shar e s 4.7 1.2 (2.5) I nve stme nts 10.0 9.2 9.1 Ne t de b t 70.1 79.0 82.5 E q uity 75.3 69.1 68.9 Ge ar ing 0.93 1.14 1.20 (1) Including Research Tax Credit previously known as a reduction in tax charges (2) In 2007 : 2.0M€ for the free share distribution plan and 1.0M€ for restructuring costs In 2006 : restructuring costs In 2005 : tangible fixed assets depreciations PCAS – F e b rua ry 2008 | 19

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend